The status of nuclear medicine techniques in the diagnosis of bone metastases in breast cancer
Jazyk angličtina Země Česko Médium print
Typ dokumentu časopisecké články
PubMed
2498049
Knihovny.cz E-zdroje
- MeSH
- karcinoembryonální antigen analýza MeSH
- kosti a kostní tkáň diagnostické zobrazování MeSH
- lidé MeSH
- nádorové biomarkery krev MeSH
- nádory kostí diagnostické zobrazování sekundární MeSH
- nádory prsu diagnostické zobrazování imunologie MeSH
- technecium 99mTc medronát MeSH
- tomografie emisní počítačová * MeSH
- Check Tag
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- karcinoembryonální antigen MeSH
- nádorové biomarkery MeSH
- technecium 99mTc medronát MeSH
In this article, the authors present their experience with the diagnosis of bone metastases in patients with breast cancer using bone scintigraphy with 99mTc phosphonate and radioimmunological determination of carcinoembryonic antigen (CEA) and tissue polypeptic antigen (TPA). In a group of 395 patients, there was agreement between tumour markers (CEA, TPA) and the results of bone scintigraphy in 331 cases (84%)--negative in 193 cases (49%) and positive (i.e. in terms of bone scintigraphy results and the presence of at least one tumour marker) in 138 cases (35%). On the basis of this good agreement of the results between bone scintigraphy and CEA and TPA levels, the authors recommend the following algorithm in monitoring patients with breast cancer: follow-up of tumour markers at several-month intervals and, any increase in their levels will refer the patient to further examination using imaging techniques including bone scintigraphy.